Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Eosinophilia Medication

  • Author: Michaelann Liss, DO; Chief Editor: Emmanuel C Besa, MD  more...
 
Updated: Nov 19, 2015
 
 

Medication Summary

Specific medications for the many infectious, allergic, and hematologic-oncologic diseases associated with eosinophilia are beyond the scope of this article, which focuses on the causes of eosinophilia. A brief overview is provided under the heading of Medical Care.

 
 
Contributor Information and Disclosures
Author

Michaelann Liss, DO Consulting Staff, Department of Hematology/Oncology, The Vancouver Clinic/South West Washington Medical Center

Michaelann Liss, DO is a member of the following medical societies: American College of Physicians, American Medical Association, American Osteopathic Association, American Society of Hematology, Pennsylvania Medical Society, American Physical Therapy Association

Disclosure: Nothing to disclose.

Coauthor(s)

Palaniandy Kogulan, MBBS, MD Assistant Director of Internal Medicine, Synergy Medical Education Alliance; Assistant Professor of Medicine, Michigan State University College of Human Medicine

Palaniandy Kogulan, MBBS, MD is a member of the following medical societies: American College of Physicians, Infectious Diseases Society of America, Michigan State Medical Society

Disclosure: Nothing to disclose.

Erik L Zeger, MD Consulting Staff, Main Line Oncology Hematology Associates

Erik L Zeger, MD is a member of the following medical societies: Alpha Omega Alpha, American Association for Cancer Research, American Society of Hematology

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Marcel E Conrad, MD Distinguished Professor of Medicine (Retired), University of South Alabama College of Medicine

Marcel E Conrad, MD is a member of the following medical societies: Alpha Omega Alpha, American Association for the Advancement of Science, American Association of Blood Banks, American Chemical Society, American College of Physicians, American Physiological Society, American Society for Clinical Investigation, American Society of Hematology, Association of American Physicians, Association of Military Surgeons of the US, International Society of Hematology, Society for Experimental Biology and Medicine, SWOG

Disclosure: Partner received none from No financial interests for none.

Chief Editor

Emmanuel C Besa, MD Professor Emeritus, Department of Medicine, Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Kimmel Cancer Center, Jefferson Medical College of Thomas Jefferson University

Emmanuel C Besa, MD is a member of the following medical societies: American Association for Cancer Education, American Society of Clinical Oncology, American College of Clinical Pharmacology, American Federation for Medical Research, American Society of Hematology, New York Academy of Sciences

Disclosure: Nothing to disclose.

Additional Contributors

Pradyumna D Phatak, MBBS, MD Chair, Division of Hematology and Medical Oncology, Rochester General Hospital; Clinical Professor of Oncology, Roswell Park Cancer Institute

Pradyumna D Phatak, MBBS, MD is a member of the following medical societies: American Society of Hematology

Disclosure: Received honoraria from Novartis for speaking and teaching.

Acknowledgements

Daniel R Lucey, MD, MPH Chief, Fellowship Program Director, Department of Internal Medicine, Division of Infectious Diseases, Washington Hospital Center; Professor, Department of Internal Medicine, Uniformed Services University of the Health Sciences

Daniel R Lucey, MD, MPH is a member of the following medical societies: Alpha Omega Alpha and American College of Physicians

Disclosure: Nothing to disclose.

References
  1. Spry CJF, ed. Eosinophils: A Comprehensive Review and Guide to the Scientific and Medical Literature. Oxford, UK: Oxford University Press; 1988.

  2. Gotlib J. Molecular classification and pathogenesis of eosinophilic disorders: 2005 update. Acta Haematol. 2005. 114(1):7-25. [Medline].

  3. Prieto R, Richter JE. Eosinophilic esophagitis in adults: an update on medical management. Curr Gastroenterol Rep. 2013 Jun. 15(6):324. [Medline].

  4. Feldman RE, Lam AC, Sadow PM, Bleier BS. P-glycoprotein is a marker of tissue eosinophilia and radiographic inflammation in chronic rhinosinusitis without nasal polyps. Int Forum Allergy Rhinol. 2013 May 15. [Medline].

  5. Kasamatsu Y, Kida T, Shigeru M, Tagashira T, Murai N, Takai E, et al. Clinically suspected acute myopericarditis with cardiac tamponade associated with peripheral blood eosinophilia presenting in early pregnancy: a case report. J Med Case Rep. 2013 May 13. 7(1):129. [Medline]. [Full Text].

  6. Tefferi A, Patnaik MM, Pardanani A. Eosinophilia: secondary, clonal and idiopathic. Br J Haematol. 2006 Jun. 133(5):468-92. [Medline].

  7. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood. 1994 May 15. 83(10):2759-79. [Medline]. [Full Text].

  8. Bain BJ. Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis. Am J Hematol. 2004 Sep. 77(1):82-5. [Medline]. [Full Text].

  9. Gotlib J, Cools J, Malone JM 3rd, et al. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood. 2004 Apr 15. 103(8):2879-91. [Medline]. [Full Text].

  10. Tefferi A. Modern diagnosis and treatment of primary eosinophilia. Acta Haematol. 2005. 114(1):52-60. [Medline].

  11. Fletcher S, Bain B. Eosinophilic leukaemia. Br Med Bull. 2007. 81-2:115-27. [Medline]. [Full Text].

  12. Arefi M, Robledo C, Peñarrubia MJ, de Coca AG, Cordero M, Hernández-Rivas JM, et al. Genomic analysis of clonal eosinophils by CGH arrays reveals new genetic regions involved in chronic eosinophilia. Eur J Haematol. 2014 Nov. 93(5):422-8. [Medline].

  13. Weller PF. Eosinophilia in travelers. Med Clin North Am. 1992 Nov. 76(6):1413-32. [Medline].

  14. Soter S, Barta I, Antus B. Predicting Sputum Eosinophilia in Exacerbations of COPD Using Exhaled Nitric Oxide. Inflammation. 2013 May 17. [Medline].

  15. Gotlib J. World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management. Am J Hematol. 2015 Nov. 90 (11):1077-89. [Medline]. [Full Text].

  16. Jain N, Cortes J, Quintas-Cardama A, et al. Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status. Leuk Res. 2009 Jun. 33(6):837-9. [Medline].

  17. Gotlib J. Tyrosine Kinase Inhibitors and Therapeutic Antibodies in Advanced Eosinophilic Disorders and Systemic Mastocytosis. Curr Hematol Malig Rep. 2015 Sep 24. 79(5):441-7. [Medline].

  18. Allen JN, Davis WB. Eosinophilic lung diseases. Am J Respir Crit Care Med. 1994 Nov. 150(5 Pt 1):1423-38. [Medline].

  19. Cohen AJ, Steigbigel RT. Eosinophilia in patients infected with human immunodeficiency virus. J Infect Dis. 1996 Sep. 174(3):615-8. [Medline].

  20. Criado PR, Criado RF, Avancini Jde M, Santi CG. Drug reaction with Eosinophilia and Systemic Symptoms (DRESS) / Drug-induced Hypersensitivity Syndrome (DIHS): a review of current concepts. An Bras Dermatol. 2012 May-Jun. 87(3):435-49. [Medline].

  21. Heimall J, Freeman A, Holland SM. Pathogenesis of hyper IgE syndrome. Clin Rev Allergy Immunol. 2009 May 19. epub ahead of print. [Medline].

  22. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009 Mar 5. 360(10):985-93. [Medline].

  23. Nand R, Bryke C, Kroft SH, et al. Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors. Leuk Res. 2009 Aug. 33(8):1144-6. [Medline].

  24. Roufosse F, Goldman M, Cogan E. Hypereosinophilic syndrome: lymphoproliferative and myeloproliferative variants. Semin Respir Crit Care Med. 2006 Apr. 27(2):158-70. [Medline].

Previous
Next
 
Indurated edematous plaques of hypereosinophilic syndrome on a patient's legs.
Erythroderma in a patient with hypereosinophilic syndrome.
Granuloma with a central core of eosinophilic debris surrounded by a peripheral palisade of epithelioid histiocytes and eosinophils from a patient with Churg-Strauss syndrome (allergic granulomatosis).
Magnified view of papules and nodules with central necrosis in a patient with Churg-Strauss syndrome (allergic granulomatosis).
High-power photomicrograph of fascia shows heavy inflammatory infiltration with numerous eosinophils, lymphocytes, and occasional plasma cells in a patient with eosinophilic fasciitis.
Lower back part of the legs in a patient with eosinophilic fasciitis shows hypopigmentation, induration, biopsy site, and asymmetric involvement.
Egg of Schistosoma hematobium, with its typical terminal spine.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.